Dharmacon Inc.

John Milligan is to stand down as CEO of Gilead Sciences Inc. at the end of the year. Former CEO and current chair John Martin will also stand down upon the appointment of a new CEO. Milligan

Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology Start-ups aim for success by reprofiling older drugs or in-licensing candidates with safety track records. Blink, and you may miss it

In this issue, we present another installment of our quarterly review of dealmaking—for January-March 2004. Our data comes from Windhover's Strategic Transactions Database , which covers deal activit

RNAi for the eye 3701 Market Street Philadelphia, PA 19104 Phone: (215) 966-6180 Fax: (215) 966-6001 Contact: Dale Pfost, PhD, President & CEO Web Site: www.acuitypharma.com Industry Segment: Ph